Comparison of Antera 3D® and TcPO2 for Evaluation of Blood Flow in Skin

Antera 3D® skin image analysis system for objective evaluation of clinical treatment efficacy in a patient with facial vitiligo

OBJECTIVE

To evaluate the changes of skin surface parameters in a patient with vitiligo using Antera 3D® Skin Image Analysis System, and to observe the clinical efficacy of the treatment of facial vitiligo.

METHODS

A patient with facial vitiligo was treated with intradermal injection of psoralen solution into the lesion combined with 308 nm excimer laser therapy. Vitiligo lesion images were captured using the Antera 3D® camera before treatment and every 2 weeks after the start of the treatment. The associated software analysis system was used to measure the parameters of melanin level, ultra-low melanin concentration, and L* value as objective indexes for the evaluation of vitiligo treatment efficacy.

RESULTS

After 10 treatments, the melanin level of the patient's skin lesions increased from 0.480 to 0.580, while the ultra-low melanin concentration and L* value decreased from 9.360 to 64.10 to 3.032 and 58.10, respectively.

CONCLUSION

The Antera 3D® skin image analysis system provides objective data, which are conducive to improving patients' treatment compliance and confidence, as well as facilitating the development of treatment plans.

New Regenerative and Anti-Aging Medicine Approach Based on Single-Stranded Alpha-1 Collagen for Neo-Collagenesis Induction: Clinical and Instrumental Experience of a New Injective Polycomponent Formulation for Dermal Regeneration

This study explores the efficacy of a novel polycomponent formulation (KARISMA Rh Collagen® FACE, Taumedika Srl, Rome, Italy), containing 200 mg/mL of non-crosslinked high-molecular-weight hyaluronic acid (HMW-HA), 200 μg/mL of a human recombinant polypeptide of collagen-1 alpha chain, and 40 mg/mL of carboxymethyl cellulose (CMC) as a regenerative medicine for skin regeneration and rejuvenation. This formulation combines non-crosslinked high-molecular-weight hyaluronic acid, human recombinant polypeptide of collagen-1 alpha chain, and carboxymethyl cellulose to stimulate collagen type I production and enhance skin hydration. This study involved 100 subjects with varying skin conditions, divided into three groups based on skin aging, smoking history, and facial scarring, to evaluate the product's effectiveness in skin regeneration and aesthetic improvement. The methodology included two injections of Karisma (2 mL for each injection) one month apart, with evaluations conducted using FACE-Q questionnaires, the SGAIS Questionnaire, and Antera 3D skin scanner measurements at baseline, 30 days, and 60 days post-treatment. The results demonstrated a significant reduction in skin roughness and an improvement in skin quality across all the groups, with no correlation between the outcomes and the patient's age. The subjective assessments also indicated high satisfaction with the treatment's aesthetic results. The analyzed data allow us to conclude that the single-stranded collagen with hyaluronic acid and carboxymethyl-cellulose formulation is able to stimulate the skin's regenerative response, yielding significant results both in vitro and, through our study, also in vivo. This new polycomponent formulation effectively stimulates skin regeneration, improving skin quality and texture, with significant aesthetic benefits perceived by patients, and a low incidence of adverse events, marking a promising advancement in regenerative medicine.